Two Differing POVs Emerge About the Hinge-Cylinder Deal
Hinge Health’s acquisition of Cylinder expands it into GI care, but experts differ on whether employers will favor convenience or specialized solutions.
Smart Toilet Sensor Startup Is Flush with $10M Funding
Throne Science — a startup selling an AI-powered toilet camera that tracks gut health, hydration and urinary function — closed a $10 million Series A funding round. CEO Scott Hickle said the goal is to become a "smoke detector for colorectal cancer,” filling a monitoring gap he noted the wearables industry has largely ignored.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Thinking with Our Gut: How the Management of GI Conditions is Evolving
Through new diagnostic methods, integrated approaches and innovative management solutions, patients no longer have to live with discomfort. Here are three major ways the GI field is evolving to better care for patients today.
From Plateau to Progress: Unleashing Growth in GI Practices Through Innovation and Alignment
In today’s environment, standing still is the riskiest strategy of all. But to move from plateau to progress, GI practices must redefine what growth looks like.
How RTO Policies Impact Employees’ Routines — And Their Digestive Health
By prioritizing digestive health through targeted benefits and workplace policies, employers can help ease the transition back to the office without compromising employee well-being.
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim
ArriVent Biopharma claims best-in-class potential in gastrointestinal cancers for its new asset, but it’s not specifying the class. It’s possible the Phase 1-ready drug goes after claudin 18.2, a hot target for GI cancer drug research that recently welcomed its first FDA-approved therapy and is in pursuit by several companies.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
The Benefits Hierarchy of Needs: Why Employers & Payers Should Prioritize Gut Health Benefits
These benefits set employees up with the resources and access to manage their health efficiently and proactively while giving employers financial savings throughout the year.
Gut Health Can Be a Workplace Equity Issue. Here’s How HR Leaders Can Prevent That
Now is a great time for employers to consider the impact GI health has on workplace equity and take steps to ensure they’re doing what they can to create an equitable workplace
Oshi Health Secures $60M To Scale Virtual Digestive Care
Oshi Health's $60 million Series C funding round was led by Oak HC/FT and included participation from existing investors Bessemer Venture Partners, Flare Capital Partners, Frist Cressey Ventures, CVS Health Ventures and Takeda Digital Ventures.
Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients
Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
The Impact of GI Disorders on Women’s Mental Health
GI disorders are complex, disruptive, and immensely stressful, with physiological, psychological, and sociological implications.
Ironwood Places $1B Bet on Biotech That Could Bring Its Next Blockbuster GI Drug
Ironwood Pharmaceuticals is paying $1 billion to acquire VectivBio, a biotech whose lead program could become a blockbuster treatment for a gastrointestinal disorder. Preliminary Phase 3 data are expected by the end of 2023.
Oshi Health targets costly GI conditions with virtual care, raises $23M
Oshi Health raised $23 million in funding, with CVS Health and Takeda joining as strategic investors. The company has built a digital health platform to help people manage GI conditions, such as Crohn’s disease and IBS.
Docbot CEO highlights how AI can be applied to gastrointestinal image analysis
Docbot CEO Andrew Ritter talked about how the predictive analytics business seeks to shake up how clinicians diagnose gastrointestinal disease by changing the way medical images are analyzed.
INVEST Pitch Perfect winner spotlight: Oshi builds digital approach for oft-overlooked GI conditions
As awareness grows around GI conditions, startup Oshi Health is building a platform to connect people to teams of clinicians and health coaches to better manage their symptoms. Judges picked the startup as the health services winner for MedCity INVEST’s Pitch Perfect contest.